• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

与新冠病毒感染更高严重程度相关的BA.5亚谱系：印度尼西亚的一项横断面研究

BA.5 sub-lineages associated with higher severity of COVID-19 infection: A cross-sectional study in Indonesia.

作者信息

Hartantri Yovita, Andriyoko Basti, Debora Josephine, Rachman Febi Ramdhani, Susandi Evan, Ferdian Ferdy, Ganiem Ahmad Rizal, Alisjahbana Bachti, Soeroto Arto Yuwono, Turbawaty Dewi Kartika

机构信息

Division of Tropical and Infectious Diseases, Internal Medicine Department, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.

Department of Clinical Pathology, Hasan Sadikin General Hospital, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.

出版信息

IJID Reg. 2024 May 9;11:100379. doi: 10.1016/j.ijregi.2024.100379. eCollection 2024 Jun.

DOI:10.1016/j.ijregi.2024.100379
PMID:38855022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11157273/
Abstract

OBJECTIVES

We aimed to compare the clinical severity and outcome among laboratory-confirmed Omicron variant cases admitted between January and December 2022.

METHODS

This is a cross-sectional study conducted in Hasan Sadikin General Hospital between January and December 2022. We enrolled patients aged ≥18 years with laboratory-confirmed Omicron infection. Data were collected from clinical records and a whole genome sequencing database. We compared the risk of severe symptoms and mortality using a logistic regression analysis adjusted for sex, age, comorbidities, and vaccination status.

RESULTS

We enrolled 255 patients and the main sub-lineages were BA.1 (16.1%), BA.2 (11.4%), BA.5 (35.7%), XBB (22.7%), and BQ.1 (14.1%). Compared with BA.1/BA.2, BA.5 sub-lineages were associated with severe symptoms (adjusted odds ratio of 2.9, 95% confidence interval 1.1-8.2, <0.05). The highest risk of severe symptoms and mortality was linked with a high number of comorbidities (adjusted odds ratio of 7.8, 95% confidence interval 1.7-22.4, <0.05). Booster vaccination was protective of severity and mortality.

CONCLUSIONS

Disease severity was associated with BA.5 sub-lineages and multiple comorbidities. Good management is particularly important for people with comorbidities. Furthermore, booster vaccination is also required to reduce severity and mortality.

摘要

目的

我们旨在比较2022年1月至12月期间实验室确诊的奥密克戎变异株病例的临床严重程度和结局。

方法

这是一项于2022年1月至12月在哈桑·萨迪金综合医院开展的横断面研究。我们纳入了年龄≥18岁且实验室确诊感染奥密克戎的患者。数据从临床记录和全基因组测序数据库中收集。我们使用经性别、年龄、合并症和疫苗接种状况调整的逻辑回归分析比较了出现严重症状和死亡的风险。

结果

我们纳入了255例患者，主要亚谱系为BA.1（16.1%）、BA.2（11.4%）、BA.5（35.7%）、XBB（22.7%）和BQ.1（14.1%）。与BA.1/BA.2相比，BA.5亚谱系与严重症状相关（调整后的优势比为2.9，95%置信区间为1.1-8.2，P<0.05）。出现严重症状和死亡的最高风险与大量合并症有关（调整后的优势比为7.8，95%置信区间为1.7-22.4，P<0.05）。加强疫苗接种对严重程度和死亡率具有保护作用。

结论

疾病严重程度与BA.5亚谱系和多种合并症相关。对于患有合并症的人群，良好的管理尤为重要。此外，还需要加强疫苗接种以降低严重程度和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/04fa4e00e74b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/1192db644e6e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/89d5bcadc4cb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/04fa4e00e74b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/1192db644e6e/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/89d5bcadc4cb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/11157273/04fa4e00e74b/gr3.jpg

相似文献

1
BA.5 sub-lineages associated with higher severity of COVID-19 infection: A cross-sectional study in Indonesia.与新冠病毒感染更高严重程度相关的BA.5亚谱系：印度尼西亚的一项横断面研究
IJID Reg. 2024 May 9;11:100379. doi: 10.1016/j.ijregi.2024.100379. eCollection 2024 Jun.
2
Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.采用检测阴性病例对照研究设计估算的针对住院治疗的疫苗效力，以及英格兰地区感染新冠病毒亚谱系BQ.1、CH.1.1和XBB.1.5后住院和出现严重后果的比较比值。
Lancet Reg Health Eur. 2023 Oct 26;35:100755. doi: 10.1016/j.lanepe.2023.100755. eCollection 2023 Dec.
3
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination.尽管基于原型的疫苗接种反复进行，但在 BA.5/ BF.7 突破性感染后，针对奥密克戎亚变种的中和作用随着病毒进化和老化而减弱。
Emerg Microbes Infect. 2023 Dec;12(2):2249121. doi: 10.1080/22221751.2023.2249121. Epub 2023 Sep 5.
4
Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults.奥密克戎变异株相关严重结局的社区居住成年人中，COVID-19 疫苗接种、既往 SARS-CoV-2 感染或混合免疫带来的保护作用。
Clin Infect Dis. 2024 May 15;78(5):1372-1382. doi: 10.1093/cid/ciad716.
5
Risk of severe outcomes among Omicron sub-lineages BA.4.6, BA.2.75, and BQ.1 compared to BA.5 in England.与 BA.5 相比，奥密克戎亚谱系 BA.4.6、BA.2.75 和 BQ.1 在英国导致严重后果的风险。
Epidemiol Infect. 2023 Oct 31;151:e189. doi: 10.1017/S0950268823001760.
6
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.既往感染人群中，与 COVID-19 mRNA 疫苗（基础免疫或加强针）接种和奥密克戎变异株 BA.1 刺突蛋白 SARS-CoV-2 感染的相关性：一项病例对照研究。
PLoS Med. 2022 Dec 1;19(12):e1004136. doi: 10.1371/journal.pmed.1004136. eCollection 2022 Dec.
7
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.南非西开普省奥密克戎变异株 BA.4 和 BA.5 驱动的疫情反弹期间与前几波相比实验室确诊的 SARS-CoV-2 感染的结果。
Int J Infect Dis. 2023 Feb;127:63-68. doi: 10.1016/j.ijid.2022.11.024. Epub 2022 Nov 24.
8
Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.辉瑞-BioNTech 疫苗对美国大型医疗体系内因 SARS-CoV-2 奥密克戎 BA.1 和 BA.2 亚系导致的住院和急诊科就诊的有效性和持久性：一项病例对照研究
Lancet Respir Med. 2023 Feb;11(2):176-187. doi: 10.1016/S2213-2600(22)00354-X. Epub 2022 Oct 7.
9
Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand.在泰国 BA.2 和 BA.4/BA.5 奥密克戎亚型占主导地位期间，异源加强疫苗可降低 COVID-19 的严重程度和死亡率。
J Microbiol Immunol Infect. 2023 Dec;56(6):1178-1186. doi: 10.1016/j.jmii.2023.10.001. Epub 2023 Oct 18.
10
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.早期估计，二价 mRNA 加强针在预防免疫功能正常成年人因奥密克戎 BA.5-和 XBB/XBB.1.5 相关亚谱系导致的有症状 SARS-CoV-2 感染方面的有效性-增加社区获得检测计划，美国，2022 年 12 月至 2023 年 1 月。
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.

本文引用的文献

1
Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.日本基于登记的观察性研究：COVID-19 症状与奥密克戎亚变体 BA.2 和 BA.5、宿主状态和临床结局的关联。
Lancet Infect Dis. 2023 Nov;23(11):1244-1256. doi: 10.1016/S1473-3099(23)00271-2. Epub 2023 Jun 30.
2
What do we know about the Arcturus XBB.1.16 subvariant?我们对大角星XBB.1.16亚变体了解多少？
BMJ. 2023 May 16;381:1074. doi: 10.1136/bmj.p1074.
3
The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: Evidence from 32 countries.
加强针接种在降低 COVID-19 年龄调整病死率中的作用：来自 32 个国家的证据。
Front Public Health. 2023 Apr 18;11:1150095. doi: 10.3389/fpubh.2023.1150095. eCollection 2023.
4
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome.SARS-CoV-2 BA.4/BA.5 奥密克戎谱系与免疫逃逸和临床结局的关联。
Nat Commun. 2023 Mar 14;14(1):1407. doi: 10.1038/s41467-023-37051-5.
5
Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia.印度尼西亚一家转诊医院收治的新冠肺炎患者死亡率相关的临床和治疗因素。
Lancet Reg Health Southeast Asia. 2023 Apr;11:100167. doi: 10.1016/j.lansea.2023.100167. Epub 2023 Feb 9.
6
A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies.关于 SARS-CoV-2 奥密克戎的详细概述：其亚变体、突变和病理生理学、临床特征、免疫状况、免疫逃逸以及治疗方法。
Viruses. 2023 Jan 5;15(1):167. doi: 10.3390/v15010167.
7
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.令人担忧的 SARS-CoV-2 BQ 和 XBB 亚型不断出现的抗体逃逸特性。
Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14.
8
Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.南非西开普省奥密克戎变异株 BA.4 和 BA.5 驱动的疫情反弹期间与前几波相比实验室确诊的 SARS-CoV-2 感染的结果。
Int J Infect Dis. 2023 Feb;127:63-68. doi: 10.1016/j.ijid.2022.11.024. Epub 2022 Nov 24.
9
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.新英格兰地区估计 SARS-CoV-2 奥密克戎 BA.2 亚变种的严重程度。
JAMA Netw Open. 2022 Oct 3;5(10):e2238354. doi: 10.1001/jamanetworkopen.2022.38354.
10
Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa.南非奥密克戎 BA.4 和 BA.5 谱系与 BA.1 和德尔塔相比的临床严重程度。
Nat Commun. 2022 Oct 4;13(1):5860. doi: 10.1038/s41467-022-33614-0.